Assorted News from the Last Week:
ARPA-H announced $50 million to expand pediatric care across the country for patients with complex medical diseases. The program–Pediatric Care eXpansion (PCX)–will connect more than 200 pediatric hospitals and care centers to securely exchange clinical and research data across the institutions. Pediatric brain tumors will be the first area of focus.
CCDI data ecosystem and AI readiness.
CAC2 Supporting Organization Jazz executed an agreement to sell the PRV gained in conjunction with last year’s FDA approval of targeted brain cancer medicine Modeyso for $200 million. In March of last year, Jazz paid $935 million to purchase biopharma Chimerix and get ahold of the then-unapproved drug, called dordaviprone, which won its FDA approval several months later.
Dual therapy shows promise for childhood brain cancer.
Analysis confirms benefit of nivolumab combo in teens with advanced Hodgkin lymphoma.
NHS admits water system probably caused fatal infections in child cancer patients in Glasgow.
Upcoming Webinars, Online Opportunities, and Meetings:
CAC2, in partnership with Courageous Parents Network (CPN), will host a webinar at noon ET on January 21, “Parenting Adolescents and Young Adults with Cancer: Navigating Your Unique Journey.” Click here for information and to register.
“Psychosocial Screening in Pediatric Cancer: Recommendations from the Advancing Childhood Cancer Experience, Science & Survivorship (ACCESS) National Consortium and Next Steps” Thursday, January 29, noon ET. Click here for more information and to register.
FDA will host Rare Disease Day, a virtual public meeting, on Monday, February 23, 2026 in global observance of Rare Disease Week. The theme is: “Moving Forward. Looking Ahead. An Event for Patients.” Click here for more information and to register.
11th International Nursing Conference on Child and Adolescent Cancer Survivorship in Philadelphia on April 30 and May 1. Click here for more information and to register.
Started in 2017, the annual MIB Agents FACTOR conference brings together the leading researchers, clinicians, and surgeons, along with patient families and OsteoWarriors (survivors, patients, and siblings of OsteoWarriors and OsteoAngels) to Make It Better for those battling this disease. This year the meeting will be in Columbus, Ohio June 25-27. Click here for information and to register.
Take Action:
The American Association for Cancer Research (AACR) is pleased to invite patient advocacy organizations working within the cancer community to exhibit in the Advocacy Partners Pavilion at the AACR Annual Meeting 2026 in San Diego, CA (April 17-22, 2026). Due to overwhelming interest from the advocacy community, AACR has opened additional booths, but availability remains limited. There is no fee to exhibit in the Advocacy Partners Pavilion. Accepted exhibitors will receive two (2) complimentary all-access passes to the conference, on-demand recordings, use of the Advocate Lounge, and five (5) complimentary exhibitor badges. Exhibitors are accepted on a first-come, first-served basis and only a few spaces remain.
The ASCO-Sponsored Patient Advocacy Booth provides an opportunity for not-for-profit patient advocacy organizations to promote their programs, services, and resources to the professional oncology community. The booth provides a venue where participants can display materials and where meeting attendees and patient advocates can meet, interact, and exchange information. Learn more.
The Conquer Cancer® Patient Advocate Award Program provides a limited number of awards for patient advocates to attend the ASCO Annual Meeting to learn of important advances in their areas of interest. Awards help cover travel, hotel, and registration expenses and are based primarily on financial need, advocacy experience, and current advocacy activities and involvement. The application period opens Monday, March 9 at 10:00 AM (ET) and closes Monday, March 16 at 5:00 PM (ET).
SUBSCRIBE
Sign up to receive a copy of CAC2’s free childhood cancer news digest in your inbox each week.
